Drug Development Pharma - February 5, 2015
FDA OKs Novo Growth Drug
The U.S. Food and Drug Administration (FDA) has granted approval of Novo Nordisk’s Norditropin® FlexPro® 30 mg/3.0 mL, a prefilled injection pen for patients with growth hormone-related disorders. The FlexPro® 30 mg/3.0 mL device complements the existing FlexPro® products. “Novo Nordisk is committed to advancing growth hormone delivery devices with patients in mind,” said Eddie Williams, […]
